{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:47:30Z","timestamp":1789832850652,"version":"4.0.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\u201cPseudoprogression\u201d following immune checkpoint inhibitors (ICI) in glioblastoma is often considered in case of radiographic progression. To better characterize the frequency of this phenomenon in glioblastoma, we reviewed the imaging response characteristics of a total of 55 patients treated with ICI in the setting of recurrent (n\u2009=\u200945) or newly diagnosed (n\u2009=\u200910) disease. There was no evidence of pseudoprogression related to ICI-monotherapy in the entire cohort.<\/jats:p>","DOI":"10.1093\/noajnl\/vdaf232","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:31:12Z","timestamp":1761046272000},"source":"Crossref","is-referenced-by-count":2,"title":["Limited evidence of pseudoprogression following immune checkpoint inhibitor (ICI) therapy in glioblastoma"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2081-5667","authenticated-orcid":false,"given":"John Y","family":"Rhee","sequence":"first","affiliation":[{"name":"Center for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston"},{"name":"Division of Adult Palliative Care, Department of Supportive Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Ospina Botero","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston"},{"name":"Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nelson","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neurosurgery, University of California San Francisco , San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun Wei","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Neurology, Stanford University Medical Center , Palo Alto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W","family":"Parsons","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R","family":"Gerstner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-0136","authenticated-orcid":false,"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital, Harvard Medical School , Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"2026041704162543500_vdaf232-B1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1215\/15228517-2007-062","article-title":"Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas","volume":"10","author":"Lamborn","year":"2008","journal-title":"Neuro-Oncol"},{"key":"2026041704162543500_vdaf232-B2","doi-asserted-by":"crossref","first-page":"91779","DOI":"10.18632\/oncotarget.21586","article-title":"Recurrent glioma clinical trial, CheckMate-143: the game is not over yet","volume":"8","author":"Filley","year":"2017","journal-title":"Oncotarget"},{"key":"2026041704162543500_vdaf232-B3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/neuonc\/nox208","article-title":"Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143","volume":"20","author":"Omuro","year":"2018","journal-title":"Neuro-Oncol"},{"key":"2026041704162543500_vdaf232-B4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11060-018-2955-9","article-title":"Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma","volume":"140","author":"Lukas","year":"2018","journal-title":"J Neurooncol"},{"key":"2026041704162543500_vdaf232-B5","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"},{"key":"2026041704162543500_vdaf232-B6","doi-asserted-by":"crossref","first-page":"10757","DOI":"10.1038\/s41467-024-54326-7","article-title":"Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort","volume":"15","author":"McFaline-Figueroa","year":"2024","journal-title":"Nat Commun"},{"key":"2026041704162543500_vdaf232-B7","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026041704162543500_vdaf232-B8","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","article-title":"Immunotherapy response assessment in neuro-oncology (iRANO): a report of the RANO working group","volume":"16","author":"Okada","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026041704162543500_vdaf232-B9","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"2026041704162543500_vdaf232-B10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"2026041704162543500_vdaf232-B11","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","article-title":"MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients","volume":"26","author":"Brandes","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026041704162543500_vdaf232-B12","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: Update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026041704162543500_vdaf232-B13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12325-011-0007-3","article-title":"AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme","volume":"28","author":"Chinot","year":"2011","journal-title":"Adv Ther"},{"key":"2026041704162543500_vdaf232-B14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/jmri.26171","article-title":"Pseudoprogression of brain tumors","volume":"48","author":"Thust","year":"2018","journal-title":"J Magn Reson Imaging JMRI"},{"key":"2026041704162543500_vdaf232-B15","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1158\/1078-0432.CCR-10-2563","article-title":"Gene expression profile correlates with T cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy","volume":"17","author":"Prins","year":"2011","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2026041704162543500_vdaf232-B16","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41582-025-01112-8","article-title":"Neurological complications of CAR T cell therapy for cancers","volume":"21","author":"Karschnia","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"2026041704162543500_vdaf232-B17","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1038\/s41467-021-26940-2","article-title":"Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma","volume":"12","author":"Lee","year":"2021","journal-title":"Nat Commun"},{"key":"2026041704162543500_vdaf232-B18","doi-asserted-by":"crossref","first-page":"798811","DOI":"10.3389\/fimmu.2021.798811","article-title":"Immune checkpoint inhibitor-induced cerebral pseudoprogression: patterns and categorization","volume":"12","author":"Urban","year":"2021","journal-title":"Front Immunol"},{"key":"2026041704162543500_vdaf232-B19","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1634\/theoncologist.2020-0085","article-title":"Defining treatment-related adverse effects in patients with glioma: distinctive features of pseudoprogression and treatment-induced necrosis","volume":"25","author":"Winter","year":"2020","journal-title":"Oncologist"},{"key":"2026041704162543500_vdaf232-B20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.20892\/j.issn.2095-3941.2019.0144","article-title":"The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy","volume":"16","author":"Jia","year":"2019","journal-title":"Cancer Biol Med"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf232\/65020015\/vdaf232.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf232\/8305590","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf232\/8305590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:16:36Z","timestamp":1776413796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf232\/8305590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf232","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,24]]},"article-number":"vdaf232"}}